In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...
Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain.
Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results